Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Monte Rosa Therapeutics (GLUE)
TipRanks (Wed, 17-Dec 12:20 PM ET)
Monte Rosa Therapeutics: Promising Progress with MRT-2359 in Advanced Prostate Cancer
TipRanks (Wed, 17-Dec 8:25 AM ET)
Why Is Monte Rosa Stock Trading Higher Today?
Benzinga (Tue, 16-Dec 2:37 PM ET)
Market Chameleon (Tue, 16-Dec 3:31 AM ET)
Monte Rosa Reports Positive Phase 1/2 Study Results
TipRanks (Tue, 16-Dec 8:00 AM ET)
Globe Newswire (Tue, 16-Dec 7:00 AM ET)
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
Globe Newswire (Mon, 15-Dec 4:01 PM ET)
Globe Newswire (Sat, 8-Nov 11:30 AM ET)
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
Globe Newswire (Thu, 6-Nov 7:00 AM ET)
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 3-Nov 7:00 AM ET)
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Monte Rosa Therapeutics trades on the NASDAQ stock market under the symbol GLUE.
As of December 19, 2025, GLUE stock price declined to $15.54 with 4,621,139 million shares trading.
GLUE has a beta of 1.72, meaning it tends to be more sensitive to market movements. GLUE has a correlation of 0.12 to the broad based SPY ETF.
GLUE has a market cap of $1.01 billion. This is considered a Small Cap stock.
Last quarter Monte Rosa Therapeutics reported $13 million in Revenue and -$.33 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.04.
In the last 3 years, GLUE traded as high as $19.17 and as low as $2.44.
The top ETF exchange traded funds that GLUE belongs to (by Net Assets): VTI, IWM, AVUV, VXF, IWN.
GLUE has outperformed the market in the last year with a return of +121.1%, while the SPY ETF gained +17.3%. In the last 3 month period, GLUE beat the market returning +124.2%, while SPY returned +3.3%. However, in the most recent 2 weeks GLUE has underperformed the stock market by returning -10.0%, while SPY returned -0.6%.
GLUE support price is $14.93 and resistance is $16.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GLUE shares will trade within this expected range on the day.